cyclacel.comCyclacel Pharmaceuticals, Inc. - Harnessing the cell cycle to treat cancer and other serious disease

s Search... Careers Contact UsMenu Toggle Leadership Board of Directors Our Science Menu Toggle Overview Fadraciclib Plogosertib Publications Pipeline News Investors Search...Harnessing the cell cycle to treat cancer and other serious diseases About Cyclacel As a clinical-stage, biopharmaceutical company, we develop innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates to address oncology and hematology indications. Who We Are Our Science Cyclacel is a pioneer in the field of cell cycle biology to treat cancer. We use insights in cancer biology to research and develop medicines that address the growing problem of resistance. Cancer cells learn to evade anticancer therapeutics and become resistant to available therapies. We aim to suppress mechanisms of resistance and reactivate the body’s own cell death mechanisms to destroy cancer cells. How It Works Our Pipeline Consistent with our mission to develop medicines that expand available options for patients, we have 2 orally-available programs in clinical development: Fadraciclib (formerly CYC065), a cyclin dependent kinase (CDK)-2 and-9 inhibitor Plogosertib (formerly CYC140), a polo-like kinase 1 (PLK1) inhibitor Explore Our Pipeline Press Releases Check out the latest news. May 08, 2024 Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results May 02, 2024 Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules April 30, 2024 Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules View All News Resources Access the latest publications on fadraciclib, CYC140, sapacitabine and related mode of actions. Oct 2022 Sarina Piha-Paul et al., A Phase 1/2, Open-label, Multi-center Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma. A poster presentation at the 34th EORTC-NCI-AACR Symposium 26-28 Oct 2022, Abstract 50. Download PDF Mar 2021 Somarelli JA et al., A precision medicine drug discovery pipeline identifies combined CDK2 and 9 inhibition as a novel therapeutic strategy in colorectal cancer. Mol Cancer Ther. 2020, 19: 2516-2527. Download PDF View All Resources Interested in Learning More About Cyclacel? Contact Us Search for:Menu Toggle Leadership Board of Directors Our Science Menu Toggle Overview Fadraciclib CYC140 Publications Pipeline News Investors Careers Contact Us Accessibility Statement Privacy Policy Disclaimer SitemapMenu Toggle Leadership Board of Directors Our Science Menu Toggle Overview Fadraciclib CYC140 Publications Pipeline News Investors Careers Contact Us Accessibility Statement Privacy Policy Disclaimer Sitemap 200 Connell Drive #1500 Berkeley Heights, NJ 07922 United States of America E: info@cyclacel.com T: +1 (908) 517 7330 F: +1 (866) 271 3466 Sign up for email alerts » Accessibility Statement Privacy Policy Disclaimer Sitemap © 2024 Cyclacel Pharmaceuticals, Inc. Paul McBarron Executive Vice President, Chief Financial Officer & Chief Operating Officer​ Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association...